(firstQuint)SHIP (Selinexor in Hormone Insensitive Prostate Cancer).

 This is a Phase 2, open-label study to explore the effect of selinexor (KPT-330) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

 Approximately 50 patients are planned for enrollment.

 Patients will receive an oral dose of Selixenor on one of three dosing schedules.

.

 SHIP (Selinexor in Hormone Insensitive Prostate Cancer)@highlight

This is an open-label, Phase 2 clinical study of the oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (mCRPC).

